Literature DB >> 3511595

Absorption of anticancer drugs through bladder epithelium.

T Mishina, H Watanabe, T Kobayashi, M Maegawa, M Nakao, S Nakagawa.   

Abstract

Fundamental and clinical evaluations of ten anticancer drugs were performed. The required qualities of an anticancer drug ideal for bladder instillation therapy are thought to be as follows: (1) a high sensitivity for bladder tumor cells; (2) a pKa which provides a high percentage of nonionized molecules in a pH 6-7 solution; (3) a log P in the range from -0.4 to -1.2 or from -7.5 to -8.0; and (4) a molecular weight over 200.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3511595     DOI: 10.1016/0090-4295(86)90372-9

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  10 in total

Review 1.  Drug delivery systems in urology--getting "smarter".

Authors:  Omid C Farokhzad; Jordan D Dimitrakov; Jeffrey M Karp; Ali Khademhosseini; Michael R Freeman; Robert Langer
Journal:  Urology       Date:  2006-09       Impact factor: 2.649

Review 2.  Intravesical drug delivery. Pharmacokinetic and clinical considerations.

Authors:  M S Highley; A T van Oosterom; R A Maes; E A De Bruijn
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

Review 3.  Antineoplastic drugs in 1990. A review (Part II).

Authors:  D J Black; R B Livingston
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

4.  Size and location of tumors influencing the effect of bladder instillation therapy.

Authors:  H Watanabe; M Nakao; S Nakagawa; H Takada
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

5.  Correlation between clinical response and urinary interleukin levels using different doses and intravesical administration schedules of interferon-alpha-2b combined with epirubicin: a pilot study.

Authors:  V Serretta; G Corselli; B Piazza; D Lio; F Gervasi; S Salerno; M Pavone-Macaluso
Journal:  Urol Res       Date:  1993

Review 6.  Optimal treatment of non-muscle invasive urothelial carcinoma including perioperative management revisited.

Authors:  Matthew J Pagano; Gina Badalato; James M McKiernan
Journal:  Curr Urol Rep       Date:  2014-11       Impact factor: 3.092

7.  Tissue disposition and plasma concentrations of idarubicin after intravesical therapy in patients with bladder tumors.

Authors:  K Mross; K Hamm; W Schultze-Seemann; K Burk; D K Hossfeld
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

8.  Intravesical oxybutynin affects bladder permeability.

Authors:  A Ersay; O C Demirtas
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

9.  Intravesical idarubicin--a phase-I study.

Authors:  W Schultze-Seemann; K Mross; K Burk; H Sommerkamp
Journal:  Urol Res       Date:  1994

10.  Intravesical instillation of adriamycin for bladder tumors.

Authors:  H Ohe; H Watanabe; T Mishina; M Kojima; S Nakagawa
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.